Akouos, Inc. (AKUS) |
| 13.29 0 (0%) 11-30 16:00 |
| Open: | 13.2 |
| High: | 13.33 |
| Low: | 13.16 |
| Volume: | 1,790,496 |
| Market Cap: | 0(M) |
| PE Ratio: | -4.69 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 13.6 |
| 52w Low: | 2.315 |
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Tue, 18 Oct 2022
Lilly to Acquire Akouos - citybiz
Tue, 18 Oct 2022
Eli Lilly to acquire hearing loss startup for up to $618M - The Business Journals
Tue, 18 Oct 2022
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss - Eli Lilly and Company
Mon, 19 Sep 2022
Jennifer Anne Wellman Net Worth (2026) - GuruFocus
Mon, 19 Sep 2022
Michael John Mckenna Net Worth (2026) - GuruFocus
Mon, 19 Sep 2022
Emmanuel Simons Net Worth (2026) - GuruFocus
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
